Disclosure under Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts more than Nifty Microcap 250 and 5.3 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Krsnaa Diagnostics' Board has approved the sale of identified diagnostic equipment for an aggregate consideration of up to ₹120 crore to identified purchasers. The move is part of an ongoing strategic shift towards an asset-light, capital-efficient operating model, and is aimed at unlocking value, improving return on capital employed, and strengthening the balance sheet. The equipment being sold is freehold and not pledged to lenders, so there is no impact on the security given to bankers. The company clarified the sale is not driven by any asset impairment and will not materially hurt profits or ongoing operations.
Positive signal for shareholders: ₹120 crore cash inflow will improve capital efficiency and ROCE without affecting core diagnostic operations, but it does not change the company's business or growth outlook in any meaningful way.